Getinge — Interim / Quarterly Report 2023

Jul 18, 2023

Interim report

April – June 2023

Comments from Mattias Perjos, CEO

Growth overshadowed by challenges in two product categories

"Getinge's sales increased organically by 1.3% during the quarter, due to the positive performance of Surgical Workflows, while the order intake fell by 4.5%. Most of the operations in Acute Care Therapies performed positively, but quality and supply challenges in the product categories of Cardiac Assist and Cardiopulmonary impacted adjusted EBITA by approximately SEK -400 M, which we announced in June. This is a top priority, and we are starting to see positive effects from the hard work. The CE certificate for our aortic balloon pump was reinstated in mid-July. In addition, we have received an extended exemption in Germany that allows us to continue to deliver our unique HLS/PLS sets for ECMO treatment without CE marking, and from the middle of the third quarter, we will start to scale up deliveries of our intra-aortic balloon catheter – one of the products that has had noticeably negative impact on sales and earnings in the quarter.

Sales for Surgical Workflows remained positive, while order intake was slightly lower following a period of robust performance. Life Science grew in its offering to traditional pharma but persisting soft demand in the biopharma segment impacted sales and the adjusted EBITA margin negatively for the business area.

The Group's sales, margins and cash flow were negatively impacted by challenges in Acute Care Therapies, an unfavorable product mix and inflation that particularly affected Surgical Workflows and large parts of Life Science. We intensify our efforts to make operations more costeffective, not least in purchasing where we see good opportunities for improvement.

Our efforts to create increased value for our customers continue. As an example, a study of the implementation of Getinge's planning tool, Torin OR Management, at Klinikum Stuttgart shows that the utilization ratio in the operating rooms increased by 6%. Such an increase is significant since the operating room is the economic engine of the hospital. In the quarter we signed an agreement to acquire High Purity New England, Inc. which has a strong position in single-use solutions for bioprocessing applications. After the end of the quarter, we received FDA 510(k) approval for the ICU ventilator Servo-air® Lite.

I look forward to the quarters ahead, focusing on acting on the challenges in Acute Care Therapies, improving productivity and creating more value for our customers in their work to deliver more and better care to more patients."

April – June 2023 in brief

• Net sales increased organically by 1.3% and the order intake declined by 4.5% organically.
• Adjusted gross profit amounted to SEK 3,314 M (3,355) and the margin was 46.2% (50.3).
• Adjusted EBITA amounted to SEK 495 M (956) and the margin was 6.9% (14.3).
• Adjusted earnings per share amounted to SEK 1.09 (2.33).
• Free cash flow amounted to SEK 276 M (129).
• After the end of the quarter:
• o The FDA granted 510(k) clearance for the ICU ventilator Servo-air® Lite.
• o The competent authority in Germany decided to extend the national exemption allowing the supply of HLS/PLS sets for ECMO treatment without CE marking from September 2023 to July 2024.
• o The notified body for certification services, TÜV SÜD, has decided to reinstate the CEcertificate for Getinge's Intra-Aortic Balloon pump Cardiosave.

Outlook 2023: Net sales for 2023 are expected to increase by 2-5% organically. (Unchanged outlook)

Summary of financial performance1)

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Order intake	7,356	7,246	14,831	14,018	29,621
Organic change, %	-4.5	-5.0	-0.9	-4.7	-5.3
Net sales	7,176	6,670	14,317	12,853	28,292
Organic change, %	1.3	-7.5	4.3	-6.9	-5.4
Adjusted gross profit	3,314	3,355	7,047	6,616	14,361
Margin, %	46.2	50.3	49.2	51.5	50.8
Adjusted EBITDA	902	1,350	2,283	2,585	5,891
Margin, %	12.6	20.2	15.9	20.1	20.8
Adjusted EBITA	495	956	1,467	1,794	4,281
Margin, %	6.9	14.3	10.2	14.0	15.1
Adjusted EBIT	442	913	1,363	1,710	4,096
Margin, %	6.2	13.7	9.5	13.3	14.5
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Margin, %	5.3	13.7	9.0	13.2	12.8
Profit before tax	305	867	1,130	1,615	3,472
Net profit for the period	216	611	809	1,149	2,516
Adjusted net profit for the period	299	644	942	1,224	2,994
Margin, %	4.2	9.7	6.6	9.5	10.6
Adjusted earnings per share, SEK	1.09	2.33	3.43	4.45	10.90
Earnings per share, SEK	0.79	2.21	2.94	4.17	9.15
Cash flow from operating activities	649	424	222	1,070	3,367
Free cash flow	276	129	-424	549	2,261

1) See page 3 for calculations of adjusted performance measures.

Every care has been taken in the translation of this Financial Report. In the event of discrepancies, the Swedish original will supersede the English translation.

January – June 2023 in brief

• Net sales increased organically by 4.3% and the order intake declined by 0.9% organically.
• Adjusted gross profit amounted to SEK 7,047 M (6,616) and the margin was 49.2% (51.5).
• Adjusted EBITA amounted to SEK 1,467 M (1,794) and the margin was 10.2% (14.0).
• Adjusted earnings per share amounted to SEK 3.43 (4.45).

• Free cash flow amounted to SEK -424 M (549).

• The lower organic order intake in Acute Care Therapies was mainly due to temporary quality and supply challenges in Cardiac Assist and a lower order intake in Critical Care. Cardiopulmonary order intake was unchanged despite challenges related to packaging. China declined significantly in the quarter in Cardiac Assist and Cardiopulmonary.

• The lower organic order intake in Life Science was mainly the result of a weaker trend in washerdisinfectors and continuing soft demand in the biopharma segment. The performance in China was particularly weak in the quarter.
• The order intake for Surgical Workflows declined organically in steam sterilizers and washerdisinfectors, but increased slightly for other products.
• Organic net sales for Acute Care Therapies increased in all key product categories except for Cardiac Assist and Cardiopulmonary, which were impacted by the previously announced quality and supply challenges. The decline in China was significant. Net sales for all other product categories increased.
• A slight organic increase was noted in net sales for Life Science as a result of the strong performance in systems for steam sterilizers and washer-disinfectors. Net sales in products for customers in the biopharma segment continued to decline, with palpable decline in China.
• Surgical Workflows increased its net sales organically in all product categories and grew substantially in North America. The improved situation regarding the supply of components also contributed positively to sales and the backlog reduced considerably.
• The strong trend in Surgical Workflows contributed to the yearon-year organic increase in net sales in capital goods.
• Net sales increased by SEK 506 M, corresponding to 7.6%.
• Net sales from acquisitions accounted for SEK 9 M or 0.1%.
• Exchange rates had an impact of SEK 411 M on sales, corresponding to 6.2%.
• Volume, mix and price affected sales by a net SEK 85 M, corresponding to 1.3%.

Group performance

Order intake

Order intake business areas, SEK M Acute Care Therapies Life Science Surgical Workflows Total	Apr-Jun 2023 3,998 930 2,428 7,356	Apr-Jun 2022 3,918 1,009 2,319 7,246	Org Δ, % -3.7 -14.3 -1.6 -4.5	Jan-Jun 2023 8,258 1,852 4,722 14,831	Jan-Jun 2022 7,683 1,994 4,341 14,018	Org Δ, % 0.6 -13.5 2.2 -0.9	Jan-Dec 2022 16,108 3,932 9,581 29,621
Order intake regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas APAC	3,341 1,439	2,978 1,713	4.7 -17.5	6,272 3,195	5,632 3,471	2.3 -10.6	11,826 7,248
EMEA	2,576	2,554	-6.5	5,364	4,914	2.3	10,548
Total	7,356	7,246	-4.5	14,831	14,018	-0.9	29,621

Net sales

Net sales business areas, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Acute Care Therapies	3,602	3,598	-5.4	7,598	7,082	0.4	15,285
Life Science	1,111	1,026	0.7	2,046	1,996	-4.6	4,026
Surgical Workflows	2,463	2,047	13.4	4,673	3,775	16.2	8,981
Total	7,176	6,670	1.3	14,317	12,853	4.3	28,292
Net sales	Apr-Jun	Apr-Jun		Jan-Jun	Jan-Jun		Jan-Dec
regions, SEK M	2023	2022	Org Δ, %	2023	2022	Org Δ, %	2022
Americas	3,024	2,650	6.7	5,965	5,187	5.6	11,467
APAC	1,514	1,676	-11.9	3,134	3,129	-3.0	6,695
EMEA	2,638	2,344	4.6	5,217	4,537	7.8	10,130
Total	7,176	6,670	1.3	14,317	12,853	4.3	28,292

Net sales specified by capital goods and recurring

recurring revenue, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Capital goods	2,774	2,450	6.8	5,324	4,632	8.0	11,101
Recurring revenue1)	4,401	4,221	-1.9	8,993	8,221	2.2	17,191
Total	7,176	6,670	1.3	14,317	12,853	4.3	28,292

1) Consumables, service and spare parts

Net sales – bridge between Q2 2022 and Q2 2023

• Currency effects impacted adjusted gross profit by SEK 182 M and adjusted EBITA by SEK 2 M during the quarter.
• The gross margin fell as a result of lower volumes related to Cardiac Assist and Cardiopulmonary in Acute Care Therapies, and in products for customers in the biopharma segment in Life Science. This contributed to negative mix effects and low capacity utilization. The margin was also impacted negatively by inflation and currency effects. This was offset by price increases and activities to enhance productivity.
• Adjusted operating expenses increased by 20.3%. The organic increase was 11.8%. (For more information, see page 4).
• Adjusted EBITA declined by SEK 461 M compared with the year-earlier period and the margin fell by 7.4 percentage points.
• Net financial items amounted to SEK -78 M mainly as a result of higher net debt and higher average interest rates.

Earnings trend

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Net sales	7,176	6,670	14,317	12,853	28,292
Adjusted gross profit	3,314	3,355	7,047	6,616	14,361
Margin, %	46.2	50.3	49.2	51.5	50.8
Adjusted operating expenses	-2,412	-2,005	-4,765	-4,031	-8,470
Adjusted EBITDA	902	1,350	2,283	2,585	5,891
Margin, %	12.6	20.2	15.9	20.1	20.8
Depreciation, amortization and write-downs of
intangible assets and tangible assets 1)	-407	-395	-816	-791	-1,610
Adjusted EBITA	495	956	1,467	1,794	4,281
Margin, %	6.9	14.3	10.2	14.0	15.1
A Amortization and write-down of acquired
intangible assets1)	-53	-43	-104	-84	-185
Adjusted EBIT	442	913	1,363	1,710	4,096
Margin, %	6.2	13.7	9.5	13.3	14.5
B Acquisition and restructuring costs	-60	-2	-79	-19	-228
C Other items affecting comparability2)	-	-	-	-	-242
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Net financial items	-78	-44	-153	-76	-154
Profit before tax	305	867	1,130	1,615	3,472
Adjusted profit before tax
(adjusted for A, B and C)	417	911	1,314	1,718	4,127
Margin, %	5.8	13.7	9.2	13.4	14.6
Taxes	-88	-255	-321	-466	-956
D Adjustment of tax 2)	-30	-12	-50	-28	-177
Adjusted net profit for the period (adjusted for A, B, C and D)	299	644	942	1,224	2,994
Margin, %	4.2	9.7	6.6	9.5	10.6
Of which, attributable to Parent Company
shareholders	296	636	934	1,212	2,969
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK (adjusted for A, B, C and D)	1.09	2.33	3.43	4.45	10.90

1) Excluding items affecting comparability (see Note 3 for depreciation, amortization and write-downs). 2) See Note 5.

Adjusted EBITA per business area1)

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	400	747	1,297	1,543	3,402
Margin, %	11.1	20.8	17.1	21.8	22.3
Life Science	114	177	247	380	650
Margin, %	10.2	17.2	12.1	19.0	16.1
Surgical Workflows	77	109	108	32	549
Margin, %	3.1	5.3	2.3	0.9	6.1
Group functions and other (incl. eliminations)	-96	-76	-185	-160	-320
Total	495	956	1,467	1,794	4,281
Margin, %	6.9	14.3	10.2	14.0	15.1

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Adjusted EBITA – bridge between Q2 2022 and Q2 2023

• Acute Care Therapies' adjusted EBITA declined by SEK 347 M mainly due lower sales volumes in Cardiac Assist and Cardiopulmonary as well as inflation. Currency effects had a positive impact. The margin fell by 9.7 percentage points.
• Life Science's adjusted EBITA declined by SEK 63 M mainly due to lower sales in products for the biopharma segment and negative currency effects, and the margin fell by 7.0 percentage points.

• Surgical Workflows' adjusted EBITA fell by SEK 32 M due to product mix, higher inflation and negative currency effects. The margin fell by 2.2 percentage points.

• Adjusted operating expenses increased by 20.3%, mainly due to negative currency effects and higher costs for purchases of services, salaries and variable remuneration, and higher costs for managing challenges in Cardiac Assist and Cardiopulmonary in Acute Care Therapies.

• Operating expenses increased organically by 11.8%.
• The negative effect of other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.
• Exchange-rate fluctuations (translation and transaction effects) impacted adjusted gross profit by SEK 182 M compared with last year, of which SEK 197 M in translation effects and SEK -15 M in transaction effects and hedging outcome.
• The change in adjusted EBITA related to currency effects is explained by translation effects of SEK 32 M and the net of transaction effects, hedging outcome and revaluation of operating receivables and liabilities in foreign currency of SEK -29 M.
• Free cash flow was impacted by a lower operating profit for the quarter.
• The change in working capital was mainly the result of lower accounts receivable and a slightly higher level of liabilities.
• The financial position remains solid, with a low share of net interestbearing debt in relation to EBITDA.

Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)1) SEK M Apr-Jun 2023 Apr-Jun 2022 Jan-Jun 2023 Jan-Jun 2022 Jan-Dec 2022 Selling expenses -1,187 -1,078 -2,369 -2,130 -4,424 Administrative expenses -953 -742 -1,832 -1,478 -3,060 Research and development costs -256 -254 -538 -496 -1,001 Other operating income and expenses -17 68 -26 72 15 Total -2,412 -2,005 -4,765 -4,031 -8,470

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Currency impact

SEK M	Apr-Jun 2023	Jan-Jun 2023
Net sales	411	892
Adjusted gross profit	182	469
Adjusted EBITDA	27	196
Adjusted EBITA	2	148
Adjusted EBIT	-1	141

Cash flow and financial position1)

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
SEK M	2023	2022	2023	2022	2022
Cash flow before changes in working capital	474	991	1,540	1,884	4,610
Changes in working capital	175	-568	-1,318	-813	-1,243
Net investments in non-current assets	-373	-295	-646	-522	-1,106
Free cash flow	276	129	-424	549	2,261
Net interest-bearing cash/debt			5,003	3,861	2,602
In relation to adjusted EBITDA 1) R12M, multiple			0.9	0.6	0.4
Net interest-bearing cash/debt, excl. pension provisions			2,460	1,242	148
In relation to adjusted EBITDA 1) R12M,
multiple			0.4	0.2	0.0

1) See Note 5 for items affecting comparability and Note 7 for alternative performance measures.

R&D expenditure was slightly higher than in the corresponding period last year as a result of increased activity,

Capitalized development costs increased by approximately 40% compared to the same period last year.

inflation and currency effects.

Research and development

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Research and development costs	-424	-373	-845	-726	-1,486
Amortization, depreciation and write-downs	-14	-11	-29	-23	-172
Research and development costs, gross	-439	-385	-874	-749	-1,658
In relation to net sales, %	6.1	5.8	6.1	5.8	5.9
Capitalized development costs	169	120	307	231	473
In relation to net sales, %	2.4	1.8	2.1	1.8	1.7
Research and development costs, net	-270	-265	-566	-519	-1,185
Amortization and write-down of capitalized development costs1)	-87	-89	-174	-181	-593

1) Capitalized development projects

Sustainability developments

Getinge's sustainability framework covers the focus areas of Quality Culture, Passionate Employees, Environmental & Social Engagement and Business Ethics & Responsible Leadership. The aim is to generate sustainable value for customers, employees and other stakeholders. At the Capital Markets Day in November 2021, targets were set for the four focus areas and Getinge reports on its quarterly performance in the relevant indicators presented below.

• Key areas Quality Culture Passionate Employees The trend in the improved customer quality index was mainly due to the higher number of open complaints, and an increase in corrective measures compared with prior quarters. Carbon emissions, energy consumption and share of
• renewable energy are continuing to perform in a positive direction due to ongoing improvements in the operations. Also in the quarter, one of the larger production units reported the purchase of international renewable energy certificate (iREC) for all of 2023. Under the GHG Protocol and SBTi, iRECs can be used to reduce the amount of carbon emissions, which means that this can also be included in reporting. As a result, the reported Scope 1 and 2 GHG emissions and the share of renewable energy have changed significantly in the first half of 2023 compared with the same period last year.

Key areas	R12 Jun 2023	Jan-Dec 2022
Quality Culture
Improved customer quality index (%)1)	61	64
Online customer training (training courses)	52,511	52,328
Passionate Employees
Sick leave (%)3)	3.2	3.2
Percentage of female employees (%)3)	37	37
Percentage of female managers (%)3)	34	33
Environmental & Social Engagement
Scope 1 & 2 GHG emissions (ton CO2 equivalents)2)	5,720	7,667
Total energy consumption in production (MWh)	76,263	78,540
Percentage of renewable energy of total energy (%)	68	60
Percentage of recycled waste (%)	45	48
Business Ethics & Responsible Leadership
Percentage of employees who completed online training
in business ethics (%)3)	89	88

1) Based on regular internal surveys for which respondents rate their level of awareness about the quality strategy and commitment in relevant initiatives and changes to quality-related KPIs.

2) Carbon emissions from production. Scope 1, including emissions from oil and gas consumption, and Scope 2, including emissions from electricity, heating and cooling (in ton CO2 equivalents)

3) Average for the period

Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures and a broad selection of products and therapies for intensive care.

Order intake and net sales

Order intake regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas	2,186	1,911	6.9	4,234	3,641	6.8	7,722
APAC	797	956	-17.9	1,875	1,955	-6.8	3,995
EMEA	1,016	1,051	-10.1	2,149	2,088	-3.4	4,391
Total	3,998	3,918	-3.7	8,258	7,683	0.6	16,108

Net sales regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas	1,832	1,755	-2.2	3,738	3,475	-1.2	7,624
APAC	764	905	-17.0	1,737	1,679	0.4	3,510
EMEA	1,006	938	-0.3	2,122	1,928	3.3	4,151
Total	3,602	3,598	-5.4	7,598	7,082	0.4	15,285

Net sales specified by

capital goods and recurring revenue, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Capital goods	790	898	-16.0	1,692	1,780	-9.8	4,099
Recurring revenue1)	2,812	2,699	-1.9	5,905	5,303	3.9	11,186
Total	3,602	3,598	-5.4	7,598	7,082	0.4	15,285

1) Consumables, service and spare parts

Earnings trend1)

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Net sales	3,602	3,598	7,598	7,082	15,285
Adjusted gross profit	1,986	2,118	4,448	4,285	9,174
Margin, %	55.1	58.9	58.5	60.5	60.0
Adjusted EBITDA	617	960	1,733	1,972	4,274
Margin, %	17.1	26.7	22.8	27.8	28.0
Depreciation, amortization and write-downs of intangible assets and tangible assets	-217	-214	-436	-429	-872
Adjusted EBITA	400	747	1,297	1,543	3,402
Margin, %	11.1	20.8	17.1	21.8	22.3

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Events in the business area in the quarter

• A new Vice President was announced for the Cardiac Assist product category.
• Transition to new EU MDR proceeding according to plan. During the quarter, MDR approval was granted for ProAQT in hemodynamic monitoring and for the Intergard Silver graft.
• In June, Getinge informed about additional quality and supply challenges in Q2, specifically relating to products in Cardiac Assist and Cardiopulmonary. Getinge is actively working to resolve these challenges and estimates that they will be resolved toward the end of 2023/H1 2024, followed by an application for regulatory approval where necessary.
• The lower organic order intake in Acute Care Therapies was mainly due to temporary quality and supply challenges in Cardiac Assist and a lower order intake in Critical Care.
• The performance was particularly weak in China, while order intake in North America was strong in all product categories except Cardiac Assist.
• Organic net sales for Acute Care Therapies increased in all key product categories except for Cardiac Assist and Cardiopulmonary, which were impacted by the previously announced quality and supply challenges. The development was markedly negative in China.
• Net sales for all other product categories increased during the quarter.
• Order bookings for deliveries in the current year are more than 20% higher than at the same time last year.
• The adjusted gross margin declined by 3.8 percentage points mainly due to lower sales volumes related to Cardiac Assist and Cardiopulmonary. The margin was also impacted by costs for an increased level of scrapping of HLS/PLS-sets being damaged during transport, as well as higher costs for input materials and personnel. This was offset by positive currency effects, price increases, a strong development in for example Critical Care, and continuing productivity enhancements.
• Adjusted operating expenses increased by 18.3% as a result of negative currency effects and increased operating expenses to manage the challenges in Cardiopulmonary and Cardiac Assist as well as higher costs for purchases of services, salaries and variable remuneration. Adjusted operating expenses increased organically by 10.8%.
• Lower adjusted gross profit and increased operating expenses contributed to a decline of SEK 347 M in adjusted EBITA compared with last year. The margin declined by 9.7 percentage points.
• Currency effects impacted sales by SEK 199, adjusted gross profit by SEK 125 M and adjusted EBITA by SEK 26 M.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

Order intake and net sales

Order intake regions, SEK M Apr-Jun 2023 Apr-Jun 2022 Org Δ, % Jan-Jun 2023 Jan-Jun 2022 Org Δ, % Jan-Dec 2022 Americas 451 379 11.3 738 752 -9.4 1,367 APAC 93 231 -61.0 195 478 -60.9 860 EMEA 386 399 -11.5 919 764 12.2 1,706 Total 930 1,009 -14.3 1,852 1,994 -13.53,932

Net sales regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas	386	354	1.6	726	671	-0.7	1,447
APAC	207	228	-13.7	373	452	-21.0	858
EMEA	518	444	7.4	946	873	0.8	1,721
Total	1,111	1,026	0.7	2,046	1,996	-4.6	4,026

Net sales specified by

capital goods and recurring revenue, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Capital goods	589	470	16.8	1,037	893	8.1	1,940
Recurring revenue1)	522	556	-12.9	1,009	1,103	-15.0	2,086
Total	1,111	1,026	0.7	2,046	1,996	-4.6	4,026

1) Consumables, service and spare parts

Earnings trend1)

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
SEK M	2023	2022	2023	2022	2022
Net sales	1,111	1,026	2,046	1,996	4,026
Adjusted gross profit	390	384	788	802	1,548
Margin, %	35.1	37.4	38.5	40.2	38.5
Adjusted EBITDA	161	216	341	457	801
Margin, %	14.5	21.0	16.7	22.9	19.9
Depreciation, amortization and write-downs of
intangible assets and tangible assets	-47	-39	-94	-78	-151
Adjusted EBITA	114	177	247	380	650
Margin, %	10.2	17.2	12.1	19.0	16.1

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Events in the business area in the quarter

• Getinge signed an agreement to acquire 100% of the shares in High Purity New England, Inc. a leading US-based company in the areas of custom single-use solutions for bioprocessing applications.
• Getinge launched ISOPRIME, an isolator with comprehensive connectivity and traceability features, optimized for commonly occurring Sterile Transfer applications.
• The lower organic order intake in Life Science was mainly the result of a weaker trend in washer-disinfectors and continuing soft demand in bioreactors. The performance in China was particularly weak in the quarter.
• The order intake increased in all product categories in Americas.
• A slight organic increase was noted in net sales for Life Science, mainly as a result of higher deliveries of steam sterilizers and washer-disinfectors in Americas and EMEA.
• Net sales in products for customers in the biopharma segment continued to decline year-on-year, particularly in China.
• The positive trend in the service business continued. However, total recurring revenue declined as a result of lower volumes of consumables targeted to the biopharma segment.
• The adjusted gross margin fell by 2.3 percentage points as a result of a negative product mix and higher costs for input goods, personnel and currency effects. Price increases contributed positively to the margin.
• Adjusted operating expenses increased by 36.0% as a result of negative currency effects and higher costs for purchases of services, salaries and variable remuneration. The organic increase was 22.5%.
• Adjusted EBITA declined by SEK 63 M and the margin fell by 7.0 percentage points as a result of a lower adjusted gross profit, higher adjusted operating expenses and negative currency effects.
• Currency effects impacted sales by SEK 78, adjusted gross profit by SEK 15 M and adjusted EBITA by SEK -11 M.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

Order intake and net sales

Order intake regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas	703	688	-5.2	1,300	1,240	-3.9	2,737
APAC	550	526	2.4	1,125	1,038	5.4	2,392
EMEA	1,174	1,104	-1.3	2,296	2,063	4.3	4,451
Total	2,428	2,319	-1.6	4,722	4,341	2.2	9,581

Net sales regions, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Americas	805	541	38.8	1,501	1,040	32.4	2,395
APAC	544	543	-2.6	1,024	999	-0.8	2,327
EMEA	1,114	963	8.1	2,149	1,736	16.3	4,259
Total	2,463	2,047	13.4	4,673	3,775	16.2	8,981

Net sales specified by

capital goods and recurring revenue, SEK M	Apr-Jun 2023	Apr-Jun 2022	Org Δ, %	Jan-Jun 2023	Jan-Jun 2022	Org Δ, %	Jan-Dec 2022
Capital goods	1,395	1,082	21.3	2,595	1,960	24.1	5,062
Recurring revenue1)	1,068	965	4.4	2,078	1,815	7.7	3,919
Total	2,463	2,047	13.4	4,673	3,775	16.2	8,981

1) Consumables, service and spare parts

Earnings trend1)

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Net sales	2,463	2,047	4,673	3,775	8,981
Adjusted gross profit	938	854	1,812	1,529	3,639
Margin, %	38.1	41.7	38.8	40.5	40.5
Adjusted EBITDA	218	248	389	311	1,127
Margin, %	8.8	12.1	8.3	8.2	12.5
Depreciation, amortization and write-downs of
intangible assets and tangible assets	-141	-139	-281	-279	-577
Adjusted EBITA	77	109	108	32	549
Margin, %	3.1	5.3	2.3	0.9	6.1

1) See Note 3 for depreciation and write-downs and Note 5 for other items affecting comparability.

Events in the business area in the quarter

The implementation of Getinge's planning tool solution, Torin OR Management, at Klinikum Stuttgart, Germany, confirms that Getinge's products help boost productivity. The study showed that the percentage of correctly planned operations increased by 39% and OR utilization was 6% more effective during the hours they were primarily in use.

• The order intake for Surgical Workflows declined organically in steam sterilizers and washerdisinfectors but increased slightly for other products.
• The order intake was unchanged in the important North American market, despite highly challenging comparative figures.
• Surgical Workflows increased its net sales organically in all product categories and grew substantially in North America, which is in line with the business area's long-term ambition.
• The improved situation regarding the supply of components also contributed positively to sales of capital goods for the quarter and the backlog reduced considerably. Recurring revenue also increased organically, although not to the same extent.
• The adjusted gross margin fell by 3.6 percentage points primarily as a result of higher costs for input goods and personnel, and negative currency effects. This was offset by higher sales volumes, price increases and productivity improvements.
• Adjusted operating expenses increased by 19.0%, mainly due to acquisitions and currency effects as well as a higher level of activity in sales and higher costs for purchases of services, salaries and variable remuneration. Organically these expenses increased by 9.7%.
• Adjusted EBITA declined by SEK 32 M and the margin declined by 2.2 percentage points.
• Currency effects impacted sales by SEK 134 M, adjusted gross profit by SEK 43 M and adjusted EBITA by SEK -7 M.

Other information

Russian invasion of Ukraine

Getinge conducts operations in Russia in accordance with international sanctions and regulations via a small sales company. The activities in the country are currently limited to fulfilling existing customer commitments and selectively participating in tender processes. Since Getinge's mission is to save lives irrespective of nationality and background, Getinge has decided not to fully withdraw from the Russian market. However, the circumstances for conducting operations in the country have gradually deteriorated. Getinge does not conduct any manufacturing operations in either Russia or Ukraine and has no major suppliers in these countries. The Group's sales in Russia and Ukraine in 2022 represented less than 1% of the Group's total net sales and equity. Despite the limited direct impact that the invasion has had on Getinge's operations in Russia and Ukraine, the Russian invasion of Ukraine may nevertheless have a negative impact on the development of the Group's earnings and position. However, it is difficult at the current time to assess the future consequences of the conflict and its impact on the Group.

Events after the end of the reporting period

US FDA 510(k) clearance for Servo-air® Lite

After the end of the period, Getinge was granted 510(k) clearance from the US Food & Drug Administration (FDA) for Servo-air® Lite. Like all Servo ventilators, it offers ICU-quality ventilation but is more geared towards spontaneously breathing patients in need of extra breathing support. With its powerful turbine and long-lasting battery backup power, it can also be operated independent of wall gas and is suitable for intrahospital transports. Servo-air Lite is expected to be available for customers in the US from September 2023.

CE-certificate reinstated for Cardiosave

The notified body for certification services, TÜV SÜD, has decided to reinstate the CE-certificate for Getinge's Intra-Aortic Balloon pump Cardiosave. On March 27, 2023, Getinge announced that the notified body, TÜV SÜD, had issued an immediate suspension of the CE certificate for intra-aortic balloon pumps for up to three months. The suspension was based on concerns related to risk management, post market surveillance and vigilance, as well as information pertaining to timeliness of field safety corrective actions.

Extended use of Article 59 to deliver HLS/PLS

On March 31, 2023, the European Commission granted an exemption to supply the HLS/PLS ECMO products without a valid CE marking to the European market based on Art. 59 Point 3 (EU) 2017/745. This exemption will expire on 30 September 2023. To continue supporting customers with life-saving products, Getinge has applied for an extension of this exemption. On 11 July 2023, the German competent authority granted BfArM an extension of the national exemption until 31 July 2024. Following the extension of the BfArM, the European Commission may decide to extend this derogation to all European Member States. The Commission's decision has not yet been taken.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with Arjo (which was distributed to shareholders in December 2017) for the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forwardlooking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Getinge's financial targets 2022-2025 and dividend policy

• Average annual organic growth in net sales: 4-6%
• Average adjusted earnings per share growth: >10%
• Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Getinge's sustainability targets 2022–2025

• Improved customer quality index >70%
• Employee commitment >70%
• CO2 neutral in own operations by 2025
• All employees trained in business ethics and responsible leadership.

Risk management

Getinge's primary risks

	Description	Potential consequences	Management
External shocks, such as geopolitical risks, natural disasters, terrorism, pandemics, etc.	These are often quickly escalating situations that affect large parts of the world, a country, a region or a specific site.	The primary consequence of this type of risk is that employees could be injured. There is also the risk of business interruptions that could have a negative impact on sales and earnings.	Active business intelligence can detect some of these risks at an early stage and the Group will then have the opportunity to adapt to the new situation. The process of further enhancing the Group's work on continuity risks continue in 2022. As part of this process, scenarios based on external shocks will also be included in the risks that Getinge proactively works on.
			On February 24, 2022, Russia invaded Ukraine. The circumstances for conducting operations in the country have gradually deteriorated and, in financial terms, the continuing war may have a negative impact on the development of the Group's earnings and position. However, it is not possible at the current time to assess the direct long-term consequences.
Quality risks from a regulatory perspective	Significant parts of Getinge's product range are covered by legislation stipulating extensive assessments, quality control and documentation.	It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted in the future by difficulties in complying with current regulations and requirements of authorities and control bodies or changes to such regulations and requirements.	To limit these risks to the greatest possible extent, Getinge conducts extensive work focused on quality and regulatory issues. The Group-wide Quality Compliance, Regulatory & Medical Affairs function has a representative in the Getinge Executive Team and also a representative on the management teams of each business area, and the function is represented in all R&D and production units. In addition, Getinge's sales force and service technicians receive relevant quality and regulatory training every other year to renew their certification. This is a requirement for representing Getinge.
			The majority of the Group's production facilities are certified according to the medical device quality standard ISO 13485 and/or the general quality standard ISO 9001. In total, the Group allocates significant resources to quality and regulatory matters in order to best manage this risk exposure, and quality is the overall priority in the Group's strategy.
			During the second quarter of 2022, an internal investigation was completed related to potential violations of German medical device laws associated with sterile packaging of HLS Sets, for which a total of five current and former Getinge employees are being investigated by the prosecution authority in Baden-Baden, Germany. As a consequence, structural changes are being made to strengthen the culture of quality in the organization. Comprehensive remediation measures regarding packaging have already been initiated and Getinge is fully cooperating with the prosecution authority. At this stage, it is not possible to estimate whether the final outcome of the public investigation will have any impact on Getinge.
			As previously reported in the first quarter of 2023, the notifying body decided to suspend the CE certificate for Getinge's HLS and PLS set for ECMO therapy and for Getinge's intra-aortic balloon pumps. As a result, the company initiated corrective actions to regain the CE certificate for these products. On June 19, 2023, Getinge announced additional quality challenges related to both of these products, which had a negative impact on sales and earnings for the quarter. These challenges are expected to be handled by the end of 2023-H1 2024, followed by an application for regulatory approval where necessary. However, unforeseen events may impact the above-mentioned timelines.
Product quality from a customer perspective	In certain cases, Getinge's products do not meet customer expectations.	Customers experiencing shortcomings in Getinge's product quality could choose other suppliers. This could entail a risk of lower sales and lower profitability over time.	Getinge applies a far-reaching quality process that aims to ensure a high and even level of quality to meet customers' legitimately high requirements. This is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly bring the right equipment on site to rectify the fault during the first service visit. Getinge closely monitors the "first time fix" factor of its services operations and works extensively to make improvements related to such faults or shortcomings.
Interruptions in supply chains / dependence on external suppliers	External suppliers that deliver critical components to the Group are a highly important part of Getinge's manufacturing process. Production disruptions may arise if these components are not supplied on schedule.	One of the potential consequences of this is that life saving equipment may not be delivered to customers as required for maintaining critical healthcare.	Getinge works actively to monitor critical deliveries. This process is initiated when the partnership is established and is then continuously monitored. The purchasing organization has tools for evaluating risk and for training in this area. The Group also works on ensuring that it has adequate levels of critical components in stock, either in its own operations or with the relevant supplier. Interruptions of critical deliveries are also an important part of activities related to business continuity risks. See "Business interruptions" below.
Digitization and innovation	Getinge's future growth depends on the company's ability to develop new and successful products, particularly in the area of digitization. Getinge's ability to innovate is a very important factor in retaining and establishing leading positions for the Group's product segments.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group's position in the market could be negatively affected if Getinge is unsuccessful in this area.	As means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls. The Group is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.
Fragmented product portfolio	Getinge's product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.	An offering to our customers that, in certain parts, is too diverse could lead to Getinge lacking the critical mass needed to conduct fully efficiency operations in all product categories.	Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the new EU Medical Device Regulation means priorities need to be made regarding the certification of products under the new regulatory framework. Products have been selected that, over the long term, will be a part of the customer offering, which will lead to increased concentration as well as streamlining.

Other risks of major importance

	Description	Potential consequences	Management
Risks related to healthcare reimbursement systems	Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.	Changes to the healthcare reimbursement system can have a major impact on individual markets by reducing or deferring grants.	It is difficult to influence this risk since these decisions are outside the Group's control but the risk is limited by Getinge being active in a large number of markets.
	Product liability risks Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability and other legal claims.	Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurances, but there is a risk that this insurance coverage may not fully cover product liability and other claims.	The best way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future claims for damages are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault. The settlement for surgical mesh implants, which Getinge announced previously, has been completed and the majority of the settlement amount was paid in the first quarter of 2023.
Risks related to intellectual property rights	Getinge's leading positions in many of the Group's product segments are based on patent and trademark rights. These rights could lead to disputes with competitors.	Getinge invests significant resources in product development that results in patent rights. There is a risk that the Group will be involved in costly disputes concerning such rights and thus a risk that invested resources will not generate the expected return if such a dispute is lost.	To secure returns on these investments, Getinge actively upholds its rights and monitors competitors' activities closely. If required, Getinge will protect its intellectual property rights through legal processes.
Financial risks	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.	Fluctuations in exchange rates and interest rates and changes in counterparties' credit profiles could adversely affect the Group's income statement and balance sheet.	Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the treasury function. For more detailed information concerning these risks, refer to Note 28 of the Annual Report.
Information and data security	Leaks of confidential information or hacking into the Group's IT system resulting in restricted availability or interruptions of business-critical systems.	Leaks of personal data could lead to high fines. Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company.	The Group's IT structure is to be considered to be decentralized, which reduces the consequence of any unauthorized access. The Group has improved user authentication during the year to prevent hacking. This work will continue in the year ahead. The Group also closely monitors critical systems to prevent hacking.
Deficiencies in cyber security	Security deficiencies in the Group's digital offering, such as connected machines at customer sites and stricter legal requirements for processing personal data.	Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.	Getinge works diligently to ensure the integrity of its equipment that is connected to the Internet. Comprehensive access testing and other measures are carried out before these solutions are offered to the Group's customers.
Business interruptions	Unforeseen and sudden events, such as natural disasters, fires, etc. that result in disruptions to production or the supply chain.	Potential interruptions and higher costs in the supply chain and production could lead to more costly or delayed deliveries or, in a worst case scenario, non-delivery to Getinge's customers. Such a situation risks negative consequences for the Group's earnings.	There is a risk of temporary business interruptions linked to a further deterioration in access to key components such as semiconductors as a result of the pandemic and uncertain global security situation. The Group continuously works on claims prevention to ensure a high level of availability and delivery reliability. External experts inspect the Group's production units on a regular basis to identify and take action on potential interruption risks, following a Group-wide standard. The process of further improving the Group's business continuity will continue in 2023.
Profitability dependent on certain products and markets	In certain cases, a relatively large share of the total profitability of a product is linked to shares in a certain market.	The consequence of such a situation is that profitability can be adversely affected if sales volumes were to decline due to a changed competitive situation in the market.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.
New competitors and new technology	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	These competitors could capture market shares from more established companies such as Getinge, resulting in a negative effect on Getinge's sales and earnings.	Getinge's long-term strategy includes active business intelligence of the competitive landscape to react to this type of competitors. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.
Laws and regulations mainly on business ethics	Breaches of competition law, anti-corruption, data privacy (such as GDPR) or trade restrictions.	Could lead to fines or penalties in one or more markets and have a negative impact on the Getinge brand.	Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. This process continued in 2023 and is ongoing. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but it is not currently possible to estimate the amount or date. Getinge has a zero tolerance policy when it comes to contraventions of these regulations. The Group's Code of Conduct is very clear in this respect.
			The Ethics & Compliance corporate function was expanded in recent years and the head of the department has been a member of the Getinge Executive Team since 2020 to further demonstrate how highly the organization prioritizes these issues. A comprehensive training program in business ethics is provided on an ongoing basis and the aim is for all employees to undergo such training at least once a year.

Getinge's business ethics regulations also apply to external distributors who sell Getinge's products in a large number of countries in which the Group does not

have its own presence.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, July 18, 2023

Johan Malmquist Chairman, AGM-elected Board member

Carl Bennet Vice Chairman, AGM-elected Board member

Johan Bygge AGM-elected Board member

Cecilia Daun Wennborg AGM-elected Board member

Mattias Perjos President & CEO, AGM-elected Board member

Fredrik Brattborn Board member Representative of the Swedish Metalworkers' Union

Barbro Fridén AGM-elected Board member

Malin Persson AGM-elected Board member

Åke Larsson Board member Representative of the Swedish Association of Graduate Engineers

This interim report is unaudited.

Dan Frohm AGM-elected Board member

Kristian Samuelsson AGM-elected Board member

Consolidated financial statements

Consolidated income statement

		Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
SEK M	Note	2023	2022	2023	2022	2022
Net sales	2	7,176	6,670	14,317	12,853	28,292
Cost of goods sold		-4,077	-3,521	-7,699	-6,650	-14,882
Gross profit	2, 3	3,099	3,150	6,618	6,203	13,410
Selling expenses		-1,307	-1,185	-2,608	-2,343	-4,870
Administrative expenses		-1,064	-855	-2,055	-1,702	-3,516
Research and development costs		-270	-265	-566	-519	-1,185
Acquisition costs		-29	-2	-44	-6	-22
Restructuring costs		-31	0	-35	-13	-206
Other operating income and expenses		-17	68	-26	72	15
Operating profit (EBIT)	2, 3	383	911	1,284	1,691	3,626
Net financial items	2	-78	-44	-153	-76	-154
Profit after financial items	2	305	867	1,130	1,615	3,472
Taxes		-88	-255	-321	-466	-956
Net profit for the period		216	611	809	1,149	2,516
Attributable to:
Parent Company shareholders		214	603	800	1,137	2,491
Non-controlling interests		2	8	9	13	25
Net profit for the period		216	611	809	1,149	2,516
Earnings per share, SEK1)		0.79	2.21	2.94	4.17	9.15
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370	272,370

1) Before and after dilution

Consolidated statement of comprehensive income

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Net profit for the period	216	611	809	1,149	2,516
Other comprehensive income
Items that cannot be restated in profit for the period
Actuarial gains/losses pertaining to defined-benefit pension plans	-	487	-	887	1,126
Tax attributable to items that cannot be restated in profit	-	-133	-	-240	-310
Items that can later be restated in profit for the period
Translation differences and hedging of net investments	1,343	1,926	1,348	2,428	3,143
Cash flow hedges	8	-47	23	-26	-15
Tax attributable to items that can be restated in profit	-21	2	-28	-5	-19
Other comprehensive income for the period, net after tax	1,330	2,235	1,343	3,044	3,924
Total comprehensive income for the period	1,547	2,846	2,152	4,193	6,440
Comprehensive income attributable to:
Parent Company shareholders	1,533	2,823	2,127	4,160	6,378
Non-controlling interests	13	23	25	33	62
Total comprehensive income for the period	1,547	2,846	2,152	4,193	6,440

Consolidated balance sheet

		June 30	June 30	December 31
SEK M	Note	2023	2022	2022
Assets
Intangible assets		28,259	26,389	27,010
Tangible assets		3,736	3,306	3,532
Right-of-use assets		1,440	1,307	1,336
Financial assets		75	48	50
Deferred tax assets		943	1,073	998
Inventories		7,225	5,907	6,232
Accounts receivable		4,537	4,276	5,275
Other current receivables		2,194	2,026	1,923
Cash and cash equivalents	6	4,434	4,147	5,676
Total assets		52,841	48,480	52,032
Equity and liabilities
Equity		31,304	28,274	30,453
Provisions for pensions, interest-bearing	6	2,543	2,619	2,454
Lease liabilities	6	1,430	1,286	1,314
Other interest-bearing liabilities	6	5,463	4,103	4,510
Deferred tax liabilities		1,186	1,101	1,150
Other provisions, long-term		783	1,128	818
Other non-interest-bearing liabilities, long-term		141	131	132
Other provisions, current		1,621	2,482	3,142
Accounts payable		2,139	1,964	2,252
Other non-interest-bearing liabilities, current		6,229	5,392	5,806
Total equity and liabilities		52,841	48,480	52,032

Changes in equity for the Group

		Other				Non
		capital		Retained		controlling	Total
SEK M	Share capital	provided	Reserves1)	earnings	Total	interests	equity
Opening balance at January 1, 2022	136	6,789	1,245	16,579	24,750	427	25,176
Total comprehensive income for the period	-	-	3,072	3,307	6,378	62	6,440
Dividend	-	-	-	-1,089	-1,089	-21	-1,111
Transactions with non
controlling interests	-	-	-	-	-	-53	-53
Closing balance at December 31, 2022	136	6,789	4,317	18,796	30,038	415	30,453
Opening balance at January 1, 2023	136	6,789	4,317	18,796	30,038	415	30,453
Total comprehensive income for the period	-	-	1,327	800	2,127	25	2,152
Dividend	-	-	-	-1,158	-1,158	-16	-1,173
Transactions with non
controlling interests	-	-	-	-	-	-128	-128
Closing balance at June 30, 2023	136	6,789	5,644	18,439	31,008	296	31,304

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Consolidated cash flow statement

SEK M	Note	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Operating activities
Operating profit (EBIT)		383	911	1,284	1,691	3,626
Add-back of depreciation, amortization and write-downs	3	465	437	925	875	2,027
Other non-cash items		-2	2	-4	0	11
Add-back of restructuring costs1)		26	0	30	13	205
Paid restructuring costs		-39	-7	-91	-36	-91
Financial items		-66	-42	-132	-82	-156
Taxes paid		-293	-310	-472	-578	-1,012
Cash flow before changes in working capital		474	991	1,540	1,884	4,610
Changes in working capital
Inventories		-125	-235	-654	-710	-998
Operating receivables		54	-139	740	360	-351
Operating liabilities2)		246	-193	-1,404	-464	107
Cash flow from operating activities		649	424	222	1,070	3,367
Investing activities
Acquisition of operations	8	-128	6	-296	-29	-365
Investments in intangible assets and tangible assets		-380	-300	-670	-539	-1,136
Divestment of non-current assets		6	5	24	18	31
Cash flow from investing activities		-502	-289	-943	-551	-1,470
Financing activities
Change in interest-bearing liabilities		974	808	865	686	1,021
Depreciation of lease liabilities		-110	-104	-219	-200	-415
Change in long-term receivables		-14	6	-23	5	5
Dividend paid Cash flow from financing activities		-1,173 -324	-1,095 -385	-1,173 -550	-1,095 -604	-1,111 -500
Cash flow for the period		-177	-250	-1,271	-84	1,397
Cash and cash equivalents at the beginning of the period		4,625	4,319	5,676	4,076	4,076
Translation differences		-15	78	28	156	203
Cash and cash equivalents at the end of the period		4,434	4,147	4,434	4,147	5,676

1) Excluding write-downs on non-current assets

2) 2023 full-year figures have been affected by payments related to the settlement regarding surgical mesh products

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2022 Annual Report and should be read in conjunction with that Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Segment overview

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Net sales, SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	3,602	3,598	7,598	7,082	15,285
Life Science	1,111	1,026	2,046	1,996	4,026
Surgical Workflows	2,463	2,047	4,673	3,775	8,981
Total	7,176	6,670	14,317	12,853	28,292
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Gross profit, SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	1,872	2,004	4,219	4,054	8,600
Life Science	365	364	738	764	1,471
Surgical Workflows	862	781	1,661	1,385	3,339
Total	3,099	3,150	6,618	6,203	13,410
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Operating profit (EBIT), SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	344	715	1,203	1,482	2,889
Life Science	107	170	232	360	600
Surgical Workflows	57	104	79	16	480
Group functions and other (incl. eliminations)1)	-125	-78	-229	-166	-343
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Net financial items	-78	-44	-153	-76	-154
Profit after financial items	305	867	1,130	1,615	3,472

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

Note 3 Depreciation, amortization and write-downs

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Acquired intangible assets	-53	-43	-104	-84	-185
Intangible assets	-150	-159	-303	-320	-875
Right-of-use assets	-120	-107	-236	-213	-433
Tangible assets	-142	-128	-282	-257	-534
Total	-465	-437	-925	-875	-2,027
of which write-downs	-5	-	-8	-1	-234

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
SEK M	2023	2022	2023	2022	2022
Cost of goods sold	-214	-206	-430	-414	-951
Selling expenses	-120	-107	-239	-214	-446
Administrative expenses	-111	-113	-223	-224	-456
Research and development costs	-14	-11	-29	-23	-172
Restructuring costs	-5	-	-5	-	-1
Total	-465	-437	-925	-875	-2,027
of which write-downs	-5	-	-8	-1	-234

Note 4 Quarterly results

	Apr-Jun	Jan-Mar	Oct-Dec	Jul-Sep	Apr-Jun	Jan-Mar	Oct-Dec	Jul-Sep
SEK M	2023	2023	2022	2022	2022	2022	2021	2021
Net sales	7,176	7,141	8,498	6,941	6,670	6,182	7,987	6,306
Cost of goods sold	-4,077	-3,622	-4,671	-3,561	-3,521	-3,129	-4,048	-3,173
Gross profit	3,099	3,519	3,828	3,380	3,150	3,053	3,939	3,133
Operating expenses	-2,717	-2,617	-2,999	-2,273	-2,239	-2,273	-2,828	-2,038
Operating profit (EBIT)	383	901	828	1,107	911	780	1,112	1,094
Net financial items	-78	-75	-47	-31	-44	-32	-36	-43
Profit after financial items	305	826	781	1,075	867	749	1,075	1,052
Taxes	-88	-233	-220	-270	-255	-210	-300	-285
Net profit for the period	216	593	561	805	611	538	775	767

Note 5 Adjustment items

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted EBITA, SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	400	747	1,297	1,543	3,402
Life Science	114	177	247	380	650
Surgical Workflows	77	109	108	32	549
Group functions and other (incl. eliminations)	-96	-76	-185	-160	-320
Total	495	956	1,467	1,794	4,281
Adjustments of EBITA, SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Specification of items affecting comparability that impact EBITA
Restructuring costs, Acute Care Therapies	-20	-	-23	-	-142
Restructuring costs, Life Science	0	0	-2	-7	-24
Restructuring costs, Surgical Workflows	-10	0	-9	-6	-39
Write-down of R&D, Acute Care Therapies	-	-	-	-	-231
Other, Acute Care Therapies1)	-	-	-	-	-11
Group functions and other (incl. eliminations)	-29	-2	-44	-6	-22
Total	-60	-2	-79	-19	-470
Items affecting comparability per segment
Acute Care Therapies	-20	-	-23	-	-384
Life Science	0	0	-2	-7	-24
Surgical Workflows	-10	0	-9	-6	-39
Group functions and other (incl. eliminations)	-29	-2	-44	-6	-22
Total	-60	-2	-79	-19	-470

1) Reported in Research and development costs

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
EBITA, SEK M	2023	2022	2023	2022	2022
Acute Care Therapies	380	747	1,274	1,543	3,018
Life Science	114	177	244	373	626
Surgical Workflows	67	109	99	26	510
Group functions and other (incl. eliminations)	-125	-78	-229	-166	-343
Total	435	954	1,388	1,776	3,811

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjustment of tax, SEK M	2023	2022	2023	2022	2022
Amortization and write-down of acquired intangible assets1)	53	43	104	84	185
Items affecting comparability	60	2	79	19	470
Adjustment items, total	112	45	183	103	655
Tax effect on adjustment items2)	-30	-12	-50	-28	-177
Adjustment for tax items affecting comparability	-	-	-	-	-
Total	-30	-12	-50	-28	-177

1) Excluding write-downs classified as items affecting comparability

2) Tax effect on tax deductible adjustment items

Note 6 Consolidated net interest-bearing debt

SEK M	June 30 2023	June 30 2022	December 31 2022
Other interest-bearing liabilities, current	1,073	387	410
Other interest-bearing liabilities, long-term	4,390	3,716	4,100
Provisions for pensions, interest-bearing	2,543	2,619	2,454
Lease liabilities, current	395	365	383
Lease liabilities, long-term	1,036	921	931
Interest-bearing liabilities	9,437	8,008	8,278
Less cash and cash equivalents	-4,434	-4,147	-5,676
Net interest-bearing cash/debt	5,003	3,861	2,602

Note 7 Key figures for the Group

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Financial and operative key figures	2023	2022	2023	2022	2022
Key figures based on Getinge's financial targets
Organic growth in net sales, %	1.3	-7.5	4.3	-6.9	-5.4
Adjusted earnings per share1), SEK	1.09	2.33	3.43	4.45	10.90
Other operative and financial key figures
Organic growth in order intake, %	-4.5	-5.0	-0.9	-4.7	-5.3
Gross margin, %	43.2	47.2	46.2	48.3	47.4
Selling expenses, % of net sales	18.2	17.8	18.2	18.2	17.2
Administrative expenses, % of net sales	14.8	12.8	14.4	13.2	12.4
Research and development costs, gross as a % of net sales	6.1	5.8	6.1	5.8	5.9
Operating margin, %	5.3	13.7	9.0	13.2	12.8
EBITDA, SEK M	848	1,348	2,209	2,566	5,653
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			26.6	45.4	39.0
Net debt/equity ratio, multiple			0.16	0.14	0.09
Net debt/Rolling 12m adjusted EBITDA, multiple			0.9	0.6	0.4
Capital employed, SEK M			34,055	29,324	31,510
Return on capital employed, %			11.0	15.2	13.0
Return on equity, %			7.2	10.6	8.9
Equity/assets ratio, %			59.2	58.3	58.5
Equity per share, SEK			114.93	103.81	111.81
Number of employees			11,098	10,986	11,082

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted gross profit, SEK M	2023	2022	2023	2022	2022
Gross profit Add-back of:	3,099	3,150	6,618	6,203	13,410
Depreciation, amortization and write-downs of intangible assets and
tangible assets	214	206	430	414	951
Other items affecting comparability	-	-	-	-	109
Adjustment for write-downs included in other items affecting
comparability	-	-	-	-	-109
Adjusted gross profit	3,314	3,355	7,047	6,616	14,361
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted EBITDA, SEK M	2023	2022	2023	2022	2022
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Add-back of:
Depreciation, amortization and write-downs of intangible assets and
tangible assets	412	395	821	791	1,842
Amortization and write-down of acquired intangible assets	53	43	104	84	185
Other items affecting comparability	-	-	-	-	242
Acquisition and restructuring costs	60	2	79	19	228
Adjustment for write-downs included in other items affecting
comparability and restructuring costs	-5	-	-5	-	-232
Adjusted EBITDA	902	1,350	2,283	2,585	5,891
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted EBITA, SEK M	2023	2022	2023	2022	2022
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Add-back of:
Amortization and write-down of acquired intangible assets	53	43	104	84	185
Other items affecting comparability	-	-	-	-	242
Acquisition and restructuring costs	60	2	79	19	228
Adjusted EBITA	495	956	1,467	1,794	4,281
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted EBIT, SEK M	2023	2022	2023	2022	2022
Operating profit (EBIT)	383	911	1,284	1,691	3,626
Add-back of:
Other items affecting comparability	-	-	-	-	242
Acquisition and restructuring costs	60	2	79	19	228
Adjusted EBIT	442	913	1,363	1,710	4,096
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Adjusted net profit for the period, SEK M	2023	2022	2023	2022	2022
Net profit for the period	216	611	809	1,149	2,516
Add-back of:
Amortization and write-down of acquired intangible assets	53	43	104	84	185
Other items affecting comparability	-	-	-	-	242
Acquisition and restructuring costs	60	2	79	19	228
Tax items affecting comparability	-	-	-	-	-
Tax on add-back items	-30	-12	-50	-28	-177
Adjusted net profit for the period	299	644	942	1,224	2,994

The calculation of adjusted earnings per share, before and after dilution, attributable to the Parent Company's shareholders, is based on the following information: Earnings (numerator), SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Adjusted net profit for the period	299	644	942	1,224	2,994
Adjusted net profit for the period attributable to non-controlling interest	-2	-8	-9	-13	-25
Adjusted net profit for the period attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share	296	636	934	1,212	2,969
Number of shares (denominator)	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK	1.09	2.33	3.43	4.45	10.90

Note 8 Acquisitions

Acquisitions in 2023

During the period, shares in the subsidiary Pulsion Medical Systems SE were acquired for SEK 128 M.

In March 2023, 100% of the shares in Ultra Clean Systems Inc. were acquired, a US manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments. Ultra Clean Systems Inc. is located near Tampa, Florida in the US, has 39 employees and generated sales of SEK 90 M in 2022. The purchase price amounted to SEK 169 M, of which SEK 107 M pertained to goodwill that is attributable to strategic advantages in the form of growth opportunities and sales-related synergies. The costs of the acquisition amounted to SEK 7 M and were charged to earnings. The acquisition did not have any material impact on Getinge's sales or earnings in the quarter. At the time of publication of this report, the acquisition analysis was preliminary.

Parent Company financial statements

Parent Company's income statement

SEK M	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Net sales	47	47	116	94	187
Administrative expenses	-101	-86	-172	-144	-336
Operating loss	-54	-39	-56	-50	-149
Result from participations in Group companies1)	2,032	3,501	2,032	3,501	3,512
Interest income and other similar income2)	13	7	22	7	13
Interest expenses and other similar expenses2)	-73	-20	-131	-61	-130
Profit after financial items	1,918	3,449	1,867	3,397	3,246
Appropriations	-	-	-	-	135
Taxes	3	-3	3	-2	-17
Net profit for the period3)	1,921	3,446	1,870	3,395	3,364

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year.

2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

3) Comprehensive income for the period corresponds to net profit for the period

Parent Company's balance sheet

SEK M	June 30 2023	June 30 2022	December 31 2022
Assets
Intangible assets	2	5	3
Tangible assets	3	4	3
Participations in Group companies	28,413	28,333	28,413
Deferred tax assets	109	103	97
Long-term receivables from Group companies	-	134	191
Current receivables from Group companies	826	560	357
Current receivables	50	49	28
Cash and cash equivalents	1,363	1,101	1,671
Total assets	30,766	30,289	30,763
Equity and liabilities
Equity	24,790	24,108	24,077
Long-term liabilities	2,970	2,044	2,544
Other provisions	21	18	16
Current liabilities to Group companies	2,160	3,915	3,908
Current liabilities	825	204	218
Total equity and liabilities	30,766	30,289	30,763

Definitions

Financial terms

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Capital goods: Durable products that are not consumed when used.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

EBIT: Operating profit.

EBITA: Operating profit (EBIT) before addback of amortization and write-down of acquired intangible assets.

EBITA margin: EBITA in relation to net sales.

EBITDA: Operating profit (EBIT) with addback of amortization, depreciation and write-downs.

EBITDA margin: EBITDA in relation to net sales.

Equity per share: Equity in relation to the number of shares at the end of the period. Equity/assets ratio: Equity in relation to total assets.

Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating liabilities:Accounts payable, other provisions and other non-interestbearing liabilities (contract liabilities, noninterest-bearing provisions for pensions, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses, accrued income and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestments of businesses.

Recurring revenue: Products that are continuously consumed as well as service, spare parts and similar items.

Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Medical terms

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE®-BetaBags: Bag that ensures contamination-free transfer of components. ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

Extracorporeal life support: Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

Grafts: Artificial vascular implants.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.

Stent: A tube for endovascular widening of blood vessels.

Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients' breath.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Teleconference

Teleconference with President & CEO Mattias Perjos and CFO Lars Sandström on July 18, 2023 at 10:00-11:00 a.m. CEST.

Fund managers, analysts and the media are invited to the teleconference.

Register via this link to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, clink on the following link. A recording will be available here for three years.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

October 23, 2023 Q3 Report 2023 February 1, 2024 Q4 Report 2023

Contact

Lars Mattsson, Head of Investor Relations +46 (0)10 335 0043 lars.mattsson@getinge.com

Jeanette Hedén Carlsson, Executive Vice President, Communications & Brand Management +46 (0)10 335 1003 jeanette.hedencarlsson@getinge.com

This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, on July 18, 2023 at 8:00 a.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs 11,000 people worldwide and the products are sold in more than 130 countries. Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993 and is included in the OMXS30 index of the 30 most actively traded shares.

Getinge AB (publ) │ Lindholmspiren 7A, 417 56 Gothenburg, Sweden │Tel: +46 (0)10 335 0000 │E-mail: info@getinge.com │ Corp. Reg. No.: 556408-5032 │ www.getinge.com